ENGNNasdaqBiological Products, (No Diagnostic Substances)Fiscal year ends October 31Also trades as ENGNW
enGene Therapeutics Inc.
Financials through Q3 FY2026, quarter ended Jul 31, 2026Last filing: 10-Q on Sep 8, 2026
$1.58−0.09 (-5.39%)
Close on Oct 19, 2026
- Market cap
- $110.18M
- P/E (TTM)
- 0.7
- Dividend yield
- 0.00%
Share price
−$7.77 (−83.10%)past year
Daily closes, adjusted for splits. Drag across the chart to measure a change.Earnings
Key statistics
Valuation at the latest close; fundamentals over fiscal , balances at Jul 31, 2026
Valuation
- Market cap
- $110.18M
- P/E ratio
- 0.7
- Price to sales
- –
- Price to book
- 0.48
- Dividend yield
- 0.00%
- Free cash flow yield
- -94.39%
Fundamentals
- Net income
- -$130.36M
- EPS, diluted
- $2.29
- Free cash flow
- -$104.00M
- Book value per share
- $3.30
- Diluted shares
- 70M
Five years at a glance
Fiscal years 2021 to 2025 and trailing twelve months, USD
Operating income
-$136.65M
Net income
-$130.36M
EPS, diluted
–
Free cash flow
-$104.00M
Reported periodTrailing twelve months